.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,763,429

« Back to Dashboard

Details for Patent: 5,763,429

Title: Method of treating prostatic diseases using active vitamin D analogues
Abstract:The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.
Inventor(s): Bishop; Charles W. (Madison, WI), Knutson; Joyce C. (Madison, WI), Mazess; Richard B. (Madison, WI)
Assignee: Bone Care International, Inc. (Madison, WI)
Filing Date:Dec 30, 1996
Application Number:08/781,910
Claims:1. A method of inhibiting the hyperproliferative activity of human prostatic neoplastic or hyperplastic cells, comprising treating the cells with an effective amount of a 1.alpha.-hydroxyvitamin D compound having a hydrocarbon moiety substituted at C-24.

2. The method of claim 1, wherein said 1.alpha.-hydroxvitamin D compound is represented by formula (I) ##STR2## wherein B and C each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R.sup.1 and R.sup.2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R.sup.1 and R.sup.2 cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C.sub.3 -C.sub.8, cyclocarbon ring; R.sup.3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X.sup.1 is hydrogen or hydroxyl, or, taken with R.sup.3, constitutes a bond when R.sup.3 is an alkenyl group, and X.sup.2 is hydrogen or hydroxyl, or, taken with R.sup.1 or R.sup.2, constitutes a double bond.

3. The method of claim 2, wherein the compound of formula (I) is 1.alpha.,24-dihydroxyvitamin D.sub.2, 1.alpha.,24-dihydroxyvitamin D.sub.4, 1.alpha.,25-dihydroxyvitamin D.sub.2, 1.alpha.,25-dihydroxyvitamin D.sub.4, 1.alpha.-hydroxyvitamin D.sub.2 or 1.alpha.-hydroxyvitamin D.sub.4.

4. The method of claim 1, wherein said treating step includes inhibiting proliferation of, and inducing and enhancing differentiation in said prostatic cells.

5. A method for the treatment of prostatic diseases characterized by abnormal cell differentiation or cell proliferation, comprising administering to a male human or animal in need of such treatment an effective proliferation-inhibiting amount of a compound of formula (I) ##STR3## wherein B and C each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R.sup.1 and R.sup.2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R.sup.1 and R.sup.2 cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C.sub.3 -C.sub.8 cyclocarbon ring; R.sup.3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X.sup.1 is hydrogen or hydroxyl, or, taken with R.sup.3, constitutes a bond when R.sup.3 is an alkenyl group, and X.sup.2 is hydrogen or hydroxyl, or, taken with R.sup.1 or R.sup.2, constitutes a double bond.

6. The method of claim 5, wherein said therapeutic amount is 0.01 .mu.g/kg/day to 2.0 .mu.g/kg/day.

7. A method of treating human prostate cancer, comprising administering to a male subject, who has prostate cancer, an effective amount of a first anticancer agent which is an active vitamin D compound to decrease or stabilize the cellular abnormal proliferative activity of the cancer, said compound or its in vivo metabolite having a VDR binding affinity substantially equivalent to the binding affinity of 1.alpha.,25-dihydroxyvitamin D.sub.3 and a hypercalcemia risk substantially lower than that of 1.alpha.,25-dihydroxyvitamin D.sub.3.

8. The method of claim 7, wherein said active vitamin D is administered in a mixture including a second anticancer agent selected from the group consisting of estramustine phosphate, prednimustine, cisplatin, 5-fluoro-uracil, melphalan, hydroxyurea, mitomycin, idarubicin, methotrexate, adriamycin and daunomycin.

9. A method of treating a human to alleviate the hyperproliferative cellular activity of prostatic cancer or hyperplasia, comprising administering to a human in need thereof a therapeutically effective amount of an active vitamin D compound having a hydrocarbon moiety substituted at C-24.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc